These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9513566)

  • 1. [Follow-up observation of intestinal Behçet disease treated with salazosulfapyridine and mesalazine for 8 years and 9 months].
    Kitauchi S; Ohata H; Kuroda R; Hirose M; Sakaguchi A; Nishi S; Nishioka S
    Nihon Shokakibyo Gakkai Zasshi; 1998 Feb; 95(2):140-4. PubMed ID: 9513566
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with intestinal Behcet disease.
    Jung YS; Hong SP; Kim TI; Kim WH; Cheon JH
    J Clin Gastroenterol; 2012; 46(5):e38-45. PubMed ID: 22298088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beneficial effect of mesalazine on esophageal ulcers in intestinal Behcet's disease.
    Sonta T; Araki Y; Koubokawa M; Tamura Y; Ochiai T; Harada N; Chijiiwa Y; Nawata H
    J Clin Gastroenterol; 2000 Mar; 30(2):195-9. PubMed ID: 10730926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical course of intestinal Behcet's disease during the first five years.
    Jung YS; Cheon JH; Park SJ; Hong SP; Kim TI; Kim WH
    Dig Dis Sci; 2013 Feb; 58(2):496-503. PubMed ID: 22899244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
    Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
    Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine.
    Bafutto M; Almeida JR; Leite NV; Oliveira EC; Gabriel-Neto S; Rezende-Filho J
    Arq Gastroenterol; 2011; 48(1):36-40. PubMed ID: 21537540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease.
    Festi D; Colecchia A
    Am J Gastroenterol; 2009 Feb; 104(2):532. PubMed ID: 19174809
    [No Abstract]   [Full Text] [Related]  

  • 9. Prescriptions for mesalazine and sulphasalazine: a prevalence estimate of patients treated for inflammatory bowel disease in Rome.
    Tebano MT; Traversa G; Da Cas R; Loizzo A
    Aliment Pharmacol Ther; 1996 Aug; 10(4):659-63. PubMed ID: 8853773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of sulphasalazine and balsalazide on histamine release from mast cells.
    Peh KH; Wan BC; Assem ES; Pearce FL
    Inflamm Res; 2007 Apr; 56 Suppl 1():S9-10. PubMed ID: 17806157
    [No Abstract]   [Full Text] [Related]  

  • 11. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
    Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
    Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
    Schroeder KW
    Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesalamine may be preferable to sulfasalazine in dermatologic therapeutics.
    Burkhart CG
    Int J Dermatol; 2006 Jun; 45(6):779-80; author reply 780. PubMed ID: 16796652
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine].
    Martínez González J; Busto Bea V; Mesonero Gismero F; Parejo Carbonell S; Garrido E; López San Román A
    Gastroenterol Hepatol; 2013 Jan; 36(1):7-10. PubMed ID: 23195755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
    Munakata A; Yoshida Y; Muto T; Tsuchiya S; Fukushima T; Hiwatashi N; Kobayashi K; Kitano A; Shimoyama T; Inoue M
    J Gastroenterol; 1995 Nov; 30 Suppl 8():108-11. PubMed ID: 8563868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Collagenous colitis. A study of 11 cases].
    Cacoub P; Sbaï A; Toan SV; Bellanger J; Hoang C; Godeau P; Piette JC
    Ann Med Interne (Paris); 2001 Sep; 152(5):299-303. PubMed ID: 11593141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon.
    Tursi A; Brandimarte G; Daffinà R
    Dig Liver Dis; 2002 Jul; 34(7):510-5. PubMed ID: 12236485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of the Concomitant Use of Low-dose Clarithromycin with an Anti-TNFα Antibody in a Patient with Intestinal Behçet Disease.
    Iwamoto J; Murakami M; Konishi N; Monma T; Ueda H; Yara S; Hirayama T; Ikegami T; Honda A; Matsuzaki Y
    Intern Med; 2018 Feb; 57(3):339-342. PubMed ID: 29093413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.